Reality Check: Biosimilar cheer for Biocon
The stock of Biocon surged as much as 16 per cent last Monday. This was after US drug regulator FDA approved Mylan’s Ogivri — a biosimilar version of Roche’s breast-cancer drug Herceptin. Mylan and Biocon are partners for biosimilar products. Mylan will market Ogivri in the US, Europe and other key markets while Biocon will manufacture and supply the product on a cost-plus-profit sharing basis...
Please Wait while comments are loading...
This article is closed for comments.
Please Email the Editor
Comments to:
Copyright ©2018, The Hindu Business Line